Overview

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Status:
NOT_YET_RECRUITING

Trial end date:
2026-06-22

Target enrollment:

Participant gender:

Summary

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI 30 kg/m2) or who are overweight (BMI 27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).

Phase:

PHASE2

Details

Lead Sponsor:

Gan and Lee Pharmaceuticals, USA

Treatments:

Tirzepatide